rlk

Rilzabrutinib (PRN1008) is a reversible covalent, selective, and orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an IC50 of 1.3 nM.

PRN694 shows extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. PRN694 is an irreversible, highly selective, and effective covalent interleukin-2-inducible T-cell kinase (ITK) and resting ly

KDRLKZ-1 is a ligand of KLHDC2 (Kd = 0.36 μM), exhibiting IC50 values of 0.21 μM and 0.31 μM in alphaLISA and time-resolved fluorescence resonance energy transfer (TR-FRET) displacement assays, respectively.

KDRLKZ-2 is a selective E3 ligase. It acts as a ligand for KLHDC2, with an IC50 value of 0.068 μM in alphaLISA assays.

KDRLKZ-3 is a selective E3 ligase. Acting as a ligand for KLHDC2, it demonstrates an IC50 value of 4.1 μM in the alphaLISA assay.